Skip to main content
. 2021 May 27;12:684344. doi: 10.3389/fimmu.2021.684344

Figure 4.

Figure 4

Pretreatment of sorafenib suppresses LPS-induced astrogliosis and COX-2 levels in wild-type mice. (A) Immunofluorescence staining with anti-GFAP and anti-COX-2 antibodies of brain slices from wild-type mice treated with sorafenib followed by LPS. (B, C) Quantification of the data in (A) (analyzed number of brain slices/images (n); GFAP: Vehicle; n=16; LPS, n=18; Sorafenib + LPS, n=17, COX-2: Vehicle, n=16; LPS, n=18; Sorafenib + LPS, n=17). *p < 0.05, **p < 0.01, Scale bar = 200 μM.